The invention provides pharmaceutically acceptable esters, salts, and prodrugs thereof.
本发明提供了药学可接受的酯类、盐类及其前体药物。
Disclosed are the ERK inhibitors of Formula (1.0) : and the pharmaceutically acceptable salts and solvates thereof.
所公开的是式(1.0)的ERK抑制剂；及其药学上可接受的盐和溶剂合物。
The formulations include a pharmaceutically acceptable carrier or are provided as part of a medical device or coating.
所述制剂包含可药用载体，或者以医用装置的一部分或涂层的形式提供。
The composition further comprises a surfactant and optionally one or more other pharmaceutically acceptable excipients.
该组合物还包含表面活性剂，以及任选的一种或多种其他可药用的赋形剂。
Also disclosed are pharmaceutical compositions comprising a compound of the invention and a pharmaceutically acceptable carrier.
还透露，均由一发明化合物和药学上可接受的载体药物成分。
This invention relates to novel compounds of the Formula Ib: that are azapeptides, and pharmaceutically acceptable salts thereof.
本发明是关于氮杂肽类新颖化合物及其医药学上可接受的盐。
The medicine composition may be prepared into different pharmaceutically acceptable forms, preferably injection and oral preparation.
该药物组合物可以制成各种药学上可接受的剂型，优选注射剂和口服制剂。
The particles can be formulated for enteral or parenteral administration by incorporating the particles into a pharmaceutically carrier.
通过将颗粒加入到药用载体中可将颗粒配制用于肠或肠胃外给药。
The medicine composition may be prepared into different pharmaceutically acceptable forms, preferably injection and orally taken preparation.
该药物组合物可制成临床或药学上可接受的剂型，优选注射剂或口服制剂。
The indirubin derivative and pharmaceutically acceptable supplementary material may be prepared into tablet, capsule or other oral preparation.
靛玉红衍生物与药学上允许的辅料加工成片剂、胶囊剂等口服制剂。
Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an effective amount of a Compound of Formula.
也公开了包括药物学上可接受的载体和有效量的式化合物的药物组合物。
The present invention uses the 2-hydroxybenzoic acid derivative represented by the specific chemical formula or its pharmaceutically acceptable salt.
本发明使用由具体化学式表示的2- 羟基苯甲酸衍生物或其药学上可接受的盐。
The air sac can also be internally filled with a certain amount of gas generant which includes carbonate and pharmaceutically acceptable organic acid.
气囊内还可以装有一定量的气体发生剂，包括碳酸盐以及药学上可接受的有机酸。
The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates.
本发明亦提供药学组合物，其包括化学式（4）的化合物、它们药学上可接受的盐类和溶剂化物。
In an alternative embodiment, a pharmaceutically active compound can be applied to exterior surfaces of the nasal elements for absorption through nasal tissue.
在另一个实施例中，药用活性化合物能被施加到鼻部构件的外表面，以便通过鼻组织吸收。
The present invention relates to aspartic protease inhibitors represented by the following structural formula (I), or a pharmaceutically acceptable salt thereof.
本发明涉及由右述结构式(I)表示的天冬氨酸蛋白酶抑制剂或其药学上可接受的盐。
The present invention discloses 6-cyproamino-8-chloropurine nucleoside compound, including pharmaceutically acceptable salt, its preparation method and application.
本发明公开了6-环丙胺基-8-氯嘌呤核苷化合物包括药学上可接受的盐及其制备方法与应用。
The acarbose is taken as the medical active component, and the acarbose is mixed with a pharmaceutically acceptable auxiliary material to form the drug composition.
它是以阿卡波糖为药用活性成份，与药学上可接受的辅料混合形成的药用组合物。
Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.
本发明还公开了同时含有CRF受体拮抗剂与可药用载体的组合物、以及使用它们的方法。
The invention relates to compounds of a general formula (1) and pharmaceutically acceptable salts, and mainly discloses 4'-substituted 13-cyclo-aza-lactone derivatives.
本发明涉及通式（1）化合物及药学上可以接受的盐，主要提出一种4”取 代的13-环氮杂内酯类的衍生物。
Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed.
本发明公开了沙利度胺及其药学可接受的前药、盐、溶剂化物、水合物或包合物的药物组合物和单一单位剂型。
The formulation comprises a glyphosate or a salt, ester or other derivative thereof, a dicarboxylic acid or a derivative thereof, and a pharmaceutically acceptable vehicle.
这种配方的构成包括草甘膦或者草甘膦的一种盐、酯或其他产物，一种二羧酸或者其产物，以及一种制药可接受的载体。
It and pharmaceutically acceptable carrier may be form medicine composition capable of being prepared into various preparation forms, such as tablet, capsule, granule, etc.
该提取物和药学上可以接受的载体组成药物组合物，可制备成多种制剂，如片剂、胶囊、软胶囊、颗粒剂、滴丸、口服液、注射剂等。
Benzopyran derivatives substituted with a benzimidazole derivative, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them.
苯并咪唑衍生物取代的苯并吡喃衍生物，其药用盐，它们的制备方法和含有它们的药物组合物。
The invention also relates to oral dosage forms comprising rosiglitazone or a pharmaceutically acceptable salt thereof and donepezil or a pharmaceutically acceptable salt thereof.
本发明还涉及口服剂型，所述口服剂型包含罗格列酮或其药学可接受盐和多奈派齐或其药学可接受盐。
This invention relates to novel compounds having the structural Formula I below: and their pharmaceutically acceptable salts or tautomers, compositions and methods of use thereof.
本发明涉及具有以下结构式i的新颖化合物及其可药用盐或互变异构体、使用它们的组合物和使用它们的方法。
In fact, one expert noted that, for decades, many American women have been pharmaceutically ending their periods with more traditional birth-control pills with no resulting problems.
事实上，一名专家指出，过去数十年来许多美国妇女已经采用更为传统的避孕药物来终止其经期，并没有出现不良后果。
The pharmaceutical composition comprises the pharmaceutical dose of the rennin inhibitor, the pharmaceutical dose of the folic acid compound and a pharmaceutically acceptable carrier.
此药物组合物包括：药用剂量的肾素抑制剂、药用剂量的叶酸类化合物、和药剂学上可接受的载体。
The gut inhabitants transform chemicals we consume into beneficial, harmless, and harmful compounds, thereby influencing the level of human exposure to pharmaceutically active compounds.
肠道菌把我们摄入的化学物质转变成有益的、无害的或者是有害的化合物，因而可以影响人体接触的具有药物活性的化合物的浓度水平。
The gut inhabitants transform chemicals we consume into beneficial, harmless, and harmful compounds, thereby influencing the level of human exposure to pharmaceutically active compounds.
肠道菌把我们摄入的化学物质转变成有益的、无害的或者是有害的化合物，因而可以影响人体接触的具有药物活性的化合物的浓度水平。
应用推荐